Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Other

Technion Research & Development Foundation Ltd

Teva Pharmaceutical Industries Limited

Bar-ilan University

Marta Weinstock-Rosin

Jeffrey Sterling

Michael Chorev

Tamar Goren

Moussa B H Youdim

Yacov Herzig

Abraham Nudelman

David Lerner

Yaacov Herzig

Victor Piryatinsky

Istvan Miskolczi

Dalia Pinkert

Hugo Gottlieb

Bronka Cohen

Shai Shoham

Moussa Bh Youdim

Shani Zeeli

Methods for treating individuals suffering from inflammation, specifically systemic inflammation including septic shock and inflammatory conditions affecting the gastrointestinal, myocardial and endocrine systems with ladostigil.

Ladostigil therapy for immunomodulation

The invention provides indole and indoline derivatives and slats thereof, compositions comprising them and uses thereof for the treatment of diseases and disorders.

Indole, indoline derivatives, compositions comprising them and uses thereof

A method for treating an individual who has been identified as having Alzheimer's disease by administering orally to the individual a therapeutically effective amount of ladostigil or a pharmaceutically active salt thereof, wherein the therapeutically effective amount is 70 mg per day, 140 mg per day, or 200 mg per day. Also, a unit dosage form of ladostigil or a pharmaceutically active salt thereof in an amount of 50 mg, 70 mg, 80 mg or 100 mg.

Propargylated aminoindans, processes for preparation, and uses thereof

The subject invention provides a method of preventing a neurodegenerative disease in a subject or oxidative stress in the brain of a subject, comprising administering to the subject a less than cholinesterase-inhibitory amount or a less than monoamine oxidase-inhibitory amount of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N'-propargyl-1-aminoindan or a salt thereof effective to prevent the neurodegenerative disease or oxidative stress in the subject.

Use of low-dose ladostigil for neuroprotection

This invention is directed to compounds of the following formula:wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is O or S, Y is halogeno, Ris hydrogen Calkyl, Ris hydrogen, Calkyl, or optionally substituted propargyl and Rand Rare each independently hydrogen, Calkyl, Caryl, Caralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Aminoindan derivatives

This invention is directed to compounds of the following formula

This invention is directed to compounds of the following formula:

Phenylethylamine derivatives

Growing community of inventors

Jerusalem, Israel

Marta Weinstock-Rosin